Loading organizations...

§ Venture Capital · Austin, TX, USA
Key people at Virtue.
Virtue AI offers an AI-native platform for security, governance, and compliance, protecting enterprise AI agents, models, and applications. It features continuous red-teaming, real-time guardrails with sub-10 millisecond response, and unified governance across 100+ languages. AgentSuite provides layered, data-driven protection for agentic AI, integrating with environments like Claude and OpenAI.
Co-founded by Bo Li and Wenbo Guo, Virtue AI arose from the critical need for robust enterprise AI security. Their insight identified escalating complexities and risks of deploying advanced AI systems. This propelled the creation of a specialized platform, ensuring secure, ethical, and compliant AI operation from development.
Virtue AI's solutions serve leading global enterprises in financial services, technology, retail, and healthcare. The company aims to mitigate enterprise AI risk significantly, establishing new benchmarks for AI security. Its vision is to foster responsible, trustworthy AI adoption by providing comprehensive protection across the AI lifecycle.
Key people at Virtue.
Virtue is a venture capital firm focused exclusively on investing in the pre-seed and seed stages of healthcare startups. Its mission centers on supporting early-stage healthcare founders with conviction-driven capital and hands-on partnership to help them achieve product-market fit and commercial success. The firm operates primarily in the U.S. with some global opportunistic investments, managing a $31.25 million Fund I and targeting a portfolio of about 25 companies. Virtue aims to build a durable, founder-first healthcare venture brand by providing not only capital but also strategic support in product development, go-to-market strategy, and talent acquisition, thereby impacting the healthcare startup ecosystem by filling a critical funding gap at the earliest stages[1].
Founded in summer 2021 by Sean Doolan, Virtue emerged to address the specific needs of pre-seed and seed healthcare companies, a segment often underserved by traditional venture capital. The firm is headquartered in Austin, Texas, and operates remotely, emphasizing flexibility and founder accessibility. Early traction includes initial investments and building a founding investment partner team to scale the firm’s operations and portfolio management capabilities[1].
Virtue rides the growing trend of specialized venture capital firms that focus deeply on niche sectors—in this case, early-stage healthcare. The timing is critical as healthcare innovation increasingly demands early capital and operational support to navigate complex regulatory, clinical, and market challenges. By concentrating on pre-seed and seed stages, Virtue addresses a funding gap that accelerates healthcare innovation and helps promising startups scale faster. This focus also aligns with broader market forces such as digital health expansion, biotech innovation, and personalized medicine, positioning Virtue as a key enabler in the healthcare startup ecosystem[1].
Looking ahead, Virtue is poised to expand its portfolio and deepen its influence in early-stage healthcare investing. Trends such as AI in healthcare, telemedicine, and biotech advancements will likely shape its investment focus. As the firm builds its brand and operational infrastructure, it could become a marquee name in healthcare venture capital, known for its founder-centric approach and sector expertise. Its success will depend on maintaining conviction-driven investing while scaling support systems to meet the complex needs of healthcare startups[1].
Virtue has 12 tracked investments across 10 companies. The latest tracked deal is $27.0M Series A in Translucent AI in March 2026.